{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T17:49:46Z","timestamp":1759600186053,"version":"3.44.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.neurol.2021.06.005","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T02:09:16Z","timestamp":1626746956000},"page":"827-833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants"],"prefix":"10.1016","volume":"177","author":[{"given":"T.P.","family":"Do","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Al-Saoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2021.06.005_bib0375","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)32160-7","article-title":"Migraine: epidemiology and systems of care","author":"Ashina","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2021.06.005_bib0380","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)32342-4","article-title":"Migraine: integrated approaches to clinical management and emerging treatments","author":"Ashina","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2021.06.005_bib0385","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","article-title":"Migraine and the trigeminovascular system-40 years and counting","volume":"18","author":"Ashina","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2021.06.005_bib0390","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMra1915327","article-title":"Migraine","volume":"383","author":"Ashina","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.neurol.2021.06.005_bib0395","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1177\/0333102420975395","article-title":"Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial","volume":"41","author":"Wienholtz","year":"2021","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurol.2021.06.005_bib0400","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0333102419864507","article-title":"PACAP27 induces migraine-like attacks in migraine patients","volume":"40","author":"Ghanizada","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurol.2021.06.005_bib0405","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/brain\/awn307","article-title":"PACAP38 induces migraine-like attacks in patients with migraine without aura","volume":"132","author":"Schytz","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2021.06.005_bib0410","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/brain\/awt369","article-title":"Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38","volume":"137","author":"Amin","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2021.06.005_bib0415","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/0333102420970889","article-title":"A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention","volume":"41","author":"Ashina","year":"2021","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurol.2021.06.005_bib0420","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s13311-017-0596-x","article-title":"Targeted pituitary adenylate cyclase-activating peptide therapies for migraine","volume":"15","author":"Vollesen","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurol.2021.06.005_bib0425","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1124\/jpet.118.253443","article-title":"Pharmacologic characterization of ALD1910, a potent humanized monoclonal antibody against the pituitary adenylate cyclase-activating peptide","volume":"369","author":"Moldovan Loomis","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neurol.2021.06.005_bib0430","unstructured":"Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04197349."},{"key":"10.1016\/j.neurol.2021.06.005_bib0435","unstructured":"A Study of LY3451838 in Participants With Migraine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04498910."},{"key":"10.1016\/j.neurol.2021.06.005_bib0440","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(88)92122-8","article-title":"Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine","volume":"331","author":"Doenicke","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2021.06.005_bib0445","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40265-019-01225-7","article-title":"Lasmiditan: first approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.neurol.2021.06.005_bib0450","first-page":"1","article-title":"62nd Annual Scientific Meeting American Headache Society\u00ae","volume":"1","year":"2020","journal-title":"Headache 60 Suppl"},{"key":"10.1016\/j.neurol.2021.06.005_bib0455","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s13311-017-0602-3","article-title":"Targeted orexin and hypothalamic neuropeptides for migraine","volume":"15","author":"Strother","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurol.2021.06.005_bib0460","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/brain\/awt320","article-title":"Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks","volume":"137","author":"Maniyar","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2021.06.005_bib0465","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/brain\/aww097","article-title":"The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks","volume":"139","author":"Schulte","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2021.06.005_bib0470","doi-asserted-by":"crossref","first-page":"107981","DOI":"10.1016\/j.neuropharm.2020.107981","article-title":"Activation orexin 1 receptors in the ventrolateral periaqueductal gray matter attenuate nitroglycerin-induced migraine attacks and calcitonin gene related peptide up-regulation in trigeminal nucleus caudalis of rats","volume":"178","author":"Kooshki","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurol.2021.06.005_bib0475","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1124\/jpet.105.090951","article-title":"Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception","volume":"315","author":"Holland","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neurol.2021.06.005_bib0480","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.nbd.2014.10.022","article-title":"Evidence for orexinergic mechanisms in migraine","volume":"74","author":"Hoffmann","year":"2015","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurol.2021.06.005_bib0485","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1111\/j.1460-9568.2006.05168.x","article-title":"Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat","volume":"24","author":"Holland","year":"2006","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.neurol.2021.06.005_bib0490","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0333102414544979","article-title":"Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis","volume":"35","author":"Chabi","year":"2015","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurol.2021.06.005_bib0495","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/brain\/awx130","article-title":"Cortical glutamate in migraine","volume":"140","author":"Zielman","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2021.06.005_bib0500","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0271678X20906902","article-title":"Glutamate levels and perfusion in pons during migraine attacks: A 3T MRI study using proton spectroscopy and arterial spin labeling","volume":"41","author":"Younis","year":"2021","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.neurol.2021.06.005_bib0505","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s10194-018-0870-2","article-title":"Effects of sildenafil and calcitonin gene-related peptide on brainstem glutamate levels: a pharmacological proton magnetic resonance spectroscopy study at 3.0T.J","volume":"19","author":"Younis","year":"2018","journal-title":"Headache Pain"},{"key":"10.1016\/j.neurol.2021.06.005_bib0510","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s13311-018-0616-5","article-title":"Glutamate and its receptors as therapeutic targets for migraine","volume":"15","author":"Hoffmann","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurol.2021.06.005_bib0515","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00726-012-1280-4","article-title":"Glutamate: a truly functional amino acid","volume":"45","author":"Brosnan","year":"2013","journal-title":"Amino Acids"},{"key":"10.1016\/j.neurol.2021.06.005_bib0520","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-pharmtox-010814-124701","article-title":"Calcitonin gene-related peptide (CGRP): a new target for migraine","volume":"55","author":"Russo","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.neurol.2021.06.005_bib0525","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1468-2982.2008.01749.x","article-title":"Effective prophylactic treatments of migraine lower plasma glutamate levels","volume":"29","author":"Ferrari","year":"2009","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurol.2021.06.005_bib0530","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1212\/WNL.40.10.1582","article-title":"Neuroexcitatory plasma amino acids are elevated in migraine","volume":"40","author":"Ferrari","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.06.005_bib0535","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1468-2982.1993.1302089.x","article-title":"Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks","volume":"13","author":"Mart\u00ednez","year":"1993","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurol.2021.06.005_bib0540","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/head.12732","article-title":"Memantine for prophylactic treatment of migraine without aura: a randomized double-blind placebo-controlled study","volume":"56","author":"Noruzzadeh","year":"2016","journal-title":"Headache J Head Face Pain"},{"key":"10.1016\/j.neurol.2021.06.005_bib0545","doi-asserted-by":"crossref","unstructured":"Shanmugam, S., Karunaikadal, K., Varadarajan, S., Krishnan, M. Memantine Ameliorates Migraine Headache. Ann. Indian Acad. Neurol. 22, 286-290.","DOI":"10.4103\/aian.AIAN_294_18"},{"key":"10.1016\/j.neurol.2021.06.005_bib0550","unstructured":"Efficacy and Safety Study of E2007 in Migraine Prophylaxis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00154063."},{"key":"10.1016\/j.neurol.2021.06.005_bib0555","unstructured":"ADX10059 Migraine Prevention Study. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00820105."},{"key":"10.1016\/j.neurol.2021.06.005_bib0560","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/ng.856","article-title":"Genome-wide association study reveals three susceptibility loci for common migraine in the general population","volume":"43","author":"Chasman","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurol.2021.06.005_bib0565","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/ng.2307","article-title":"Genome-wide association analysis identifies susceptibility loci for migraine without aura","volume":"44","author":"Freilinger","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurol.2021.06.005_bib0570","doi-asserted-by":"crossref","first-page":"8294","DOI":"10.1038\/s41598-021-87503-5","article-title":"Changes in the gene expression profile during spontaneous migraine attacks","volume":"11","author":"Kogelman","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurol.2021.06.005_bib0575","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1177\/0333102417712719","article-title":"Functional interactions between transient receptor potential M8 and transient receptor potential V1 in the trigeminal system: Relevance to migraine pathophysiology","volume":"38","author":"Kayama","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurol.2021.06.005_bib0580","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jpain.2006.09.005","article-title":"Critical evaluation of the colocalization between calcitonin gene-related peptide, substance P, transient receptor potential vanilloid subfamily type 1 immunoreactivities, and isolectin B4 binding in primary afferent neurons of the rat and mouse","volume":"8","author":"Price","year":"2007","journal-title":"J pain"},{"key":"10.1016\/j.neurol.2021.06.005_bib0585","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010342","article-title":"TRP channels in the focus of trigeminal nociceptor sensitization contributing to primary headaches","author":"Dux","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurol.2021.06.005_bib0590","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s10194-021-01235-5","article-title":"Petasin and isopetasin reduce CGRP release from trigeminal afferents indicating an inhibitory effect on TRPA1 and TRPV1 receptor channels","volume":"22","author":"Kleeberg-Hartmann","year":"2021","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2021.06.005_bib0595","unstructured":"Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02132429."},{"key":"10.1016\/j.neurol.2021.06.005_bib0600","unstructured":"A Study of LY3526318 in Healthy Women. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04183283."},{"key":"10.1016\/j.neurol.2021.06.005_bib0605","unstructured":"A Study of LY3526318 in Healthy Participants. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03977974."},{"issue":"Suppl","key":"10.1016\/j.neurol.2021.06.005_bib0610","first-page":"S17","article-title":"The Concise Guide To Pharmacology 2017\/18: G protein-coupled receptors","volume":"174","author":"Alexander","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.neurol.2021.06.005_bib0615","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/head.12152","article-title":"pH-evoked dural afferent signaling is mediated by ASIC3 and is sensitized by mast cell mediators","volume":"53","author":"Yan","year":"2013","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.06.005_bib0620","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/ana.23653","article-title":"Acid-sensing ion channel 1: a novel therapeutic target for migraine with aura","volume":"72","author":"Holland","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2021.06.005_bib0625","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","article-title":"Pharmacology of antisense drugs","volume":"57","author":"Bennett","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.neurol.2021.06.005_bib0630","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1089\/nat.2018.0754","article-title":"IONIS-PKK Rx a novel antisense inhibitor of prekallikrein and bradykinin production","volume":"29","author":"Ferrone","year":"2019","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.neurol.2021.06.005_bib0635","unstructured":"Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03108469."},{"key":"10.1016\/j.neurol.2021.06.005_bib0640","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/brain\/awy300","article-title":"Meningeal contribution to migraine pain: a magnetic resonance angiography study","volume":"142","author":"Khan","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2021.06.005_bib0645","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1177\/0333102417719753","article-title":"Reproducibility of migraine-like attacks induced by phosphodiesterase-3-inhibitor cilostazol","volume":"38","author":"Khan","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurol.2021.06.005_bib0650","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1093\/brain\/awu244","article-title":"Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase","volume":"137","author":"Guo","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2021.06.005_bib0655","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1177\/0333102419882474","article-title":"Investigation of distinct molecular pathways in migraine induction using calcitonin gene-related peptide and sildenafil","volume":"39","author":"Younis","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurol.2021.06.005_bib0660","unstructured":"NCT01981499 | Migraine Clinical Trial | pfpfizeruscom."},{"key":"10.1016\/j.neurol.2021.06.005_bib0665","unstructured":"A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01981499."},{"key":"10.1016\/j.neurol.2021.06.005_bib0670","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00213-008-1372-8","article-title":"Studies of pharmacokinetic and pharmacodynamic properties of isoallopregnanolone in healthy women","volume":"203","author":"Hedstr\u00f6m","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neurol.2021.06.005_bib0675","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/jnnp-2018-320113","article-title":"Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials","volume":"90","author":"Reuter","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2021.06.005_bib0680","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1177\/0333102419876920","article-title":"Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial","volume":"39","author":"Diener","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurol.2021.06.005_bib0685","first-page":"42","article-title":"IHC 2019 Abstracts (IHC-PO-002)","volume":"39","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurol.2021.06.005_bib0690","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s10194-016-0684-z","article-title":"Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual\/menstrually related migraine: an open-label study","volume":"17","author":"Grazzi","year":"2016","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2021.06.005_bib0695","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s10194-015-0582-9","article-title":"Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study","volume":"16","author":"Kinfe","year":"2015","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2021.06.005_bib0700","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1212\/WNL.0b013e3182825055","article-title":"Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial","volume":"80","author":"Schoenen","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.06.005_bib0705","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s10194-015-0551-3","article-title":"Transcutaneous supraorbital neurostimulation in \u2018de novo\u2019 patients with migraine without aura: the first Italian experience","volume":"16","author":"Russo","year":"2015","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2021.06.005_bib0710","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10072-017-2916-7","article-title":"Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial","volume":"38","author":"Di Fiore","year":"2017","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurol.2021.06.005_bib0715","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jpain.2017.03.012","article-title":"Migraine Prevention Using Different Frequencies of Transcutaneous Occipital Nerve Stimulation: A Randomized Controlled Trial","volume":"18","author":"Liu","year":"2017","journal-title":"J. Pain"},{"key":"10.1016\/j.neurol.2021.06.005_bib0720","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s10194-020-01204-4","article-title":"Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials","volume":"21","author":"Moisset","year":"2020","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.neurol.2021.06.005_bib0725","doi-asserted-by":"crossref","first-page":"e2488","DOI":"10.1212\/WNL.0000000000011930","article-title":"Effect of Adrenomedullin on Migraine-Like Attacks in Patients With Migraine","volume":"96","author":"Ghanizada","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.06.005_bib0730","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/ana.26072","article-title":"Amylin analog pramlintide induces migraine-like attacks in patients","volume":"89","author":"Ghanizada","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2021.06.005_bib0735","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awab136","article-title":"Opening of ATP sensitive potassium channels causes migraine attacks with aura","author":"Al-Karagholi","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2021.06.005_bib0740","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1093\/brain\/awz199","article-title":"Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine","volume":"142","author":"Al-Karagholi","year":"2019","journal-title":"Brain"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003537872100610X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003537872100610X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:42:23Z","timestamp":1758519743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003537872100610X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":74,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S003537872100610X"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2021.06.005","relation":{},"ISSN":["0035-3787"],"issn-type":[{"type":"print","value":"0035-3787"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2021.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}